Client News

Home/Client News

AB Science announces that FDA green-lights U.S. patient enrollment in masitinib Phase 3 study following IND clearance in metastatic castrate-resistant prostate cancer eligible to chemotherapy

AB Science SA (NYSE Euronext – FR0010557264 – AB) today announces that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application to conduct its masitinib Phase 3 study (AB12003) in metastatic castrate-resistant prostate cancer (mCRPC) eligible to chemotherapy.

By |2020-01-09T12:46:03-04:00January 9th, 2020|Client News|Comments Off on AB Science announces that FDA green-lights U.S. patient enrollment in masitinib Phase 3 study following IND clearance in metastatic castrate-resistant prostate cancer eligible to chemotherapy

Valneva Expands its Commercial Operations with the Opening of its French Commercial Office

Saint-Herblain (France), January 9, 2020 – Valneva SE (“Valneva” or “the Company”) today announced a further expansion of its global commercial infrastructure with the opening of a French commercial office in Lyon. The fully owned commercial subsidiary, Valneva France SAS, will take direct control of sales and marketing of IXIARO® and DUKORAL® in France with […]

By |2020-01-09T12:44:48-04:00January 9th, 2020|Client News|Comments Off on Valneva Expands its Commercial Operations with the Opening of its French Commercial Office

Compugen Highlights Recent Accomplishments and Previews Upcoming Milestones

HOLON, Israel, Jan. 9, 2020 /PRNewswire/ — Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today provided an update on upcoming milestones for its COM701 and COM902 clinical programs and highlighted 2019 accomplishments.

By |2020-01-09T12:43:11-04:00January 9th, 2020|Client News|Comments Off on Compugen Highlights Recent Accomplishments and Previews Upcoming Milestones

Oncolytics Biotech® Announces Key Opinion Leader Call Conducted by ROTH Capital Partners to Discuss Multiple Myeloma

SAN DIEGO and CALGARY, Alberta, Jan. 9, 2020 /PRNewswire/ — Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that ROTH Capital Partners (ROTH) will conduct a Key Opinion Leader call today at 10:30 am ET for their institutional clients. The call, “Proteasome […]

By |2020-01-09T12:42:18-04:00January 9th, 2020|Client News|Comments Off on Oncolytics Biotech® Announces Key Opinion Leader Call Conducted by ROTH Capital Partners to Discuss Multiple Myeloma

ADMA Biologics Announces Preliminary Fourth Quarter and Full Year 2019 Revenues and Provides 2020 Strategic Outlook

RAMSEY, N.J. and BOCA RATON, Fla., Jan. 09, 2020 (GLOBE NEWSWIRE) — ADMA Biologics, Inc. (ADMA), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and for the prevention of certain infectious diseases, today announced its preliminary unaudited fourth […]

By |2020-01-09T12:41:36-04:00January 9th, 2020|Client News|Comments Off on ADMA Biologics Announces Preliminary Fourth Quarter and Full Year 2019 Revenues and Provides 2020 Strategic Outlook

Infinity Pharmaceuticals to Present Corporate Overview at 38th Annual J.P. Morgan Global Healthcare Conference

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) announced […]

By |2020-01-09T12:40:59-04:00January 9th, 2020|Client News|Comments Off on Infinity Pharmaceuticals to Present Corporate Overview at 38th Annual J.P. Morgan Global Healthcare Conference

DarioHealth Strengthens Management Team With Appointment of Digital Health Veteran Rick Anderson as President and General Manager, North America

NEW YORK, Jan. 9, 2020 /PRNewswire/ — DarioHealth Corp. (Nasdaq: DRIO) (“DarioHealth” or the “Company”), a pioneer in the global digital therapeutics market, announced today the appointment of Richard Anderson as its President and General Manager of North America, effective January 13, 2020.  Reporting to Chief Executive Officer Erez Raphael, […]

By |2020-01-09T12:40:20-04:00January 9th, 2020|Client News|Comments Off on DarioHealth Strengthens Management Team With Appointment of Digital Health Veteran Rick Anderson as President and General Manager, North America

Infinity Pharmaceuticals Raises $20 Million Through an Innovative Non-Dilutive Asset-Backed Financing from BVF

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) (“Infinity”) today announced a $20 million non-dilutive asset-backed financing with BVF Partners L.P. (“BVF”), Infinity’s largest shareholder. This investment by BVF entails no equity to be issued by Infinity and has its sole recourse in potential royalty payments due on future sales of patidegib, a hedgehog pathway inhibitor discovered by […]

By |2020-01-09T12:39:44-04:00January 9th, 2020|Client News|Comments Off on Infinity Pharmaceuticals Raises $20 Million Through an Innovative Non-Dilutive Asset-Backed Financing from BVF

Cellectar Biosciences to Host a CLR 131 Clinical Data Call with Its Phase 2 Lead Investigator on February 19, 2020

FLORHAM PARK, N.J., Jan. 09, 2020 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that it will host a Clinical Data Call on Wednesday, February 19, 2020 at 10:30 am Eastern Time.

By |2020-01-09T12:39:07-04:00January 9th, 2020|Client News|Comments Off on Cellectar Biosciences to Host a CLR 131 Clinical Data Call with Its Phase 2 Lead Investigator on February 19, 2020

Immutep Expands Part C of TACTI-002 Due to Positive Data

SYDNEY, Australia, Jan. 09, 2020 (GLOBE NEWSWIRE) — Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, provides an update on its TACTI-002 and AIPAC studies for its lead product candidate, eftilagimod alpha (“efti” or “IMP321”).

By |2020-01-09T12:38:28-04:00January 9th, 2020|Client News|Comments Off on Immutep Expands Part C of TACTI-002 Due to Positive Data

Foamix Announces AMZEEQ™ (minocycline) Topical Foam Available in Pharmacies Nationwide on January 13th for the Treatment of Moderate to Severe Acne

REHOVOT, Israel and BRIDGEWATER, N.J., Jan. 9, 2020/PRNewswire/ — Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company, today announced that its novel AMZEEQ™ (minocycline) topical foam, 4% will be available on January 13, 2020 by prescription for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in adults and pediatric […]

By |2020-01-09T12:37:47-04:00January 9th, 2020|Client News|Comments Off on Foamix Announces AMZEEQ™ (minocycline) Topical Foam Available in Pharmacies Nationwide on January 13th for the Treatment of Moderate to Severe Acne

EDAP Issues Letter to Shareholders

LYON, France, January 9, 2020 — EDAP TMS SA (EDAP) (“the Company”), the global leader in Robotic Energy-based Therapies, today issued the following letter to shareholders:

By |2020-01-09T12:36:47-04:00January 9th, 2020|Client News|Comments Off on EDAP Issues Letter to Shareholders

LifeSci Public Relations Becomes LifeSci Communications, Reflecting Agency’s Evolution

NEW YORK, Jan. 08, 2020 (GLOBE NEWSWIRE) — LifeSci Public Relations LLC, a global communications and marketing agency, today announced it has rebranded to LifeSci Communications.

“The new name – LifeSci Communications – emphasizes our comprehensive services as a strategic partner for the life sciences industry,” said Matt Middleman, M.D., CEO of LifeSci Communications. “From our […]

By |2020-01-08T12:56:41-04:00January 8th, 2020|Client News|Comments Off on LifeSci Public Relations Becomes LifeSci Communications, Reflecting Agency’s Evolution

LifeSci Capital Announces Transition to Fully Independent, High-Conviction Research Coverage

NEW YORK, Jan. 08, 2020 (GLOBE NEWSWIRE) — LifeSci Capital LLC, a research-driven investment bank focused on the life sciences, today announced its transition to providing fully independent, high-conviction equity research coverage of selected companies in the life sciences through the expansion of its Alpha Series and KOL Series research products.

The Alpha Series focuses […]

By |2020-01-08T12:55:44-04:00January 8th, 2020|Client News|Comments Off on LifeSci Capital Announces Transition to Fully Independent, High-Conviction Research Coverage

Inspire Medical Systems, Inc. to Present at the 38th Annual J.P. Morgan Healthcare Conference

MINNEAPOLIS, Jan. 07, 2020 (GLOBE NEWSWIRE) — Inspire Medical Systems, Inc. (INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will be presenting at the 38th Annual J.P. Morgan Healthcare Conference on January […]

By |2020-01-08T12:51:16-04:00January 8th, 2020|Client News|Comments Off on Inspire Medical Systems, Inc. to Present at the 38th Annual J.P. Morgan Healthcare Conference

Theravance Biopharma Announces Presentation at the 38th Annual J.P. Morgan Healthcare Conference

DUBLIN, Jan. 7, 2020 /PRNewswire/ — Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, will webcast its presentation at the 38thAnnual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2020. The presentation is scheduled for 8:30 a.m. PT (

By |2020-01-08T12:50:35-04:00January 8th, 2020|Client News|Comments Off on Theravance Biopharma Announces Presentation at the 38th Annual J.P. Morgan Healthcare Conference

Basilea at the 38th Annual J. P. Morgan Healthcare Conference – significant progress in Cresemba commercialization and R&D portfolio in 2019

Basel, Switzerland, January 08, 2020 – […]

By |2020-01-08T12:49:56-04:00January 8th, 2020|Client News|Comments Off on Basilea at the 38th Annual J. P. Morgan Healthcare Conference – significant progress in Cresemba commercialization and R&D portfolio in 2019

Kodiak Sciences to Present at 38th Annual J.P. Morgan Healthcare Conference

PALO ALTO, Calif., Jan. […]

By |2020-01-08T12:49:14-04:00January 8th, 2020|Client News|Comments Off on Kodiak Sciences to Present at 38th Annual J.P. Morgan Healthcare Conference

BioLineRx to Present at the 2020 Biotech Showcase

TEL AVIV, Israel, Jan. […]

By |2020-01-08T12:48:34-04:00January 8th, 2020|Client News|Comments Off on BioLineRx to Present at the 2020 Biotech Showcase

Compugen Announces Appointment of Dr. Oliver Froescheis as Senior Vice President, Corporate and Business Development

HOLON, Israel, Jan. 8, 2020 /PRNewswire/ — Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced the appointment of Oliver Froescheis, Ph.D., as Senior Vice President, Corporate and Business Development. In his role, Dr. Froescheis will oversee the Company’s business development strategy […]

By |2020-01-08T12:47:52-04:00January 8th, 2020|Client News|Comments Off on Compugen Announces Appointment of Dr. Oliver Froescheis as Senior Vice President, Corporate and Business Development

Arcturus Therapeutics Appoints Steve Hughes, M.D., as Chief Development Officer

SAN DIEGO, Jan. 08, 2020 (GLOBE NEWSWIRE) — Arcturus Therapeutics (the “Company”, NASDAQ: ARCT), a leading messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases, today announced the appointment of Steve Hughes, M.D., as Chief Development Officer, effective January 2, 2020. Dr. Hughes brings over twenty years of […]

By |2020-01-08T12:47:12-04:00January 8th, 2020|Client News|Comments Off on Arcturus Therapeutics Appoints Steve Hughes, M.D., as Chief Development Officer

UroGen to Present at 38th Annual J.P. Morgan Healthcare Conference

UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options, today announced that Liz Barrett, President and Chief Executive Officer, will present at the 38th Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2020 at 1:30 PM Pacific Time. […]

By |2020-01-08T12:46:35-04:00January 8th, 2020|Client News|Comments Off on UroGen to Present at 38th Annual J.P. Morgan Healthcare Conference

VBL Therapeutics Announces Publication of Phase 2 and Phase 3 Data of VB-111 in Recurrent Glioblastoma Supporting Continued Development in Investigator-Sponsored Study

TEL AVIV, Israel, Jan. 08, 2020 (GLOBE NEWSWIRE) — VBL Therapeutics (VBLT) today announced the publication of clinical data from the Phase 2 and Phase 3 studies of VB-111 (ofranergene obadenovec) in recurrent glioblastoma (rGBM) in two manuscripts published in the peer-reviewed journal Neuro-Oncology, the official journal of the Society for Neuro-Oncology.

By |2020-01-08T12:45:55-04:00January 8th, 2020|Client News|Comments Off on VBL Therapeutics Announces Publication of Phase 2 and Phase 3 Data of VB-111 in Recurrent Glioblastoma Supporting Continued Development in Investigator-Sponsored Study

TYME Announces First Patient Dosed in TYME-88-Panc Pivotal Trial to Evaluate SM-88 as Oral Treatment for Patients with Metastatic Pancreatic Cancer

NEW YORK, Jan. 08, 2020 (GLOBE NEWSWIRE) — Tyme Technologies, Inc. (TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced that the first pancreatic cancer patient has been dosed in Part 2 of the TYME-88-Panc pivotal trial designed to support approval of SM-88 (racemetyrosine) for the third-line treatment of patients with […]

By |2020-01-08T12:45:08-04:00January 8th, 2020|Client News|Comments Off on TYME Announces First Patient Dosed in TYME-88-Panc Pivotal Trial to Evaluate SM-88 as Oral Treatment for Patients with Metastatic Pancreatic Cancer

Molecular Templates Provides Corporate Update and Outlines 2020 Milestones

AUSTIN, Texas, Jan. 08, 2020 (GLOBE NEWSWIRE) — Molecular Templates, Inc., (MTEM) a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), provided a corporate update and outlined expected 2020 milestones.

By |2020-01-08T12:43:46-04:00January 8th, 2020|Client News|Comments Off on Molecular Templates Provides Corporate Update and Outlines 2020 Milestones

Serum Institute of India Private Limited has achieved World Health Organization (WHO) prequalification for PNEUMOSIL®, containing CRM197 produced in Pfenex Expression Technology

SAN DIEGO, Jan. 08, 2020 (GLOBE NEWSWIRE) — Pfenex Inc. (NYSE American: PFNX) today announced that Serum Institute of India Private Limited (Serum Institute) achieved World Health Organization (WHO) prequalification for Pneumosil, a 10-valent pneumococcal conjugate vaccine. Pneumosil contains the recombinant carrier protein CRM197 produced by Serum Institute under a license to the Pfenex Expression […]

By |2020-01-08T12:43:10-04:00January 8th, 2020|Client News|Comments Off on Serum Institute of India Private Limited has achieved World Health Organization (WHO) prequalification for PNEUMOSIL®, containing CRM197 produced in Pfenex Expression Technology

Arena Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference on January 16

SAN DIEGO, Jan. 8, 2020 /PRNewswire/ — Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Amit D. Munshi, the Company’s President and Chief Executive Officer, will present a corporate update at the 38th Annual J.P. Morgan Healthcare Conference on Thursday, January 16, at 1:00 PM ET […]

By |2020-01-08T12:42:30-04:00January 8th, 2020|Client News|Comments Off on Arena Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference on January 16

CohBar Discovers Novel Peptide Inhibitors of CXCR4, a Key Regulator of Tumor Growth and Metastasis

MENLO PARK, Calif., Jan. 08, 2020 (GLOBE NEWSWIRE) — CohBar, Inc. (CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat chronic diseases and extend healthy lifespan, today announced the discovery of a series of novel mitochondrial peptide analogs with potent in vitro activity as selective inhibitors of C-X-C Chemokine Receptor […]

By |2020-01-08T12:41:30-04:00January 8th, 2020|Client News|Comments Off on CohBar Discovers Novel Peptide Inhibitors of CXCR4, a Key Regulator of Tumor Growth and Metastasis

Sequana Medical announces first patient enrolled in RED DESERT – REpeated Dose alfapump® DSR study for Treatment of diuretic-resistant heart failure patients

GHENT, Belgium, Jan. 07, 2020 (GLOBE NEWSWIRE) — Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, today announces that the first patient has been enrolled in the first-in-human repeated dose study of alfapump DSR (Direct Sodium Removal) for the treatment of […]

By |2020-01-07T17:00:22-04:00January 7th, 2020|Client News|Comments Off on Sequana Medical announces first patient enrolled in RED DESERT – REpeated Dose alfapump® DSR study for Treatment of diuretic-resistant heart failure patients

Transgene and NEC Start Two Clinical Trials with TG4050, an Individualized AI-Powered Cancer Vaccine for Ovarian and Head & Neck Cancers

Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and NEC Corporation (NEC; TSE: 6701), a leader in IT and network technologies, today announced that the first patients have been enrolled in the first-in-human trials evaluating TG4050, an individualized therapeutic vaccine based on the myvac™ […]

By |2020-01-07T16:58:51-04:00January 7th, 2020|Client News|Comments Off on Transgene and NEC Start Two Clinical Trials with TG4050, an Individualized AI-Powered Cancer Vaccine for Ovarian and Head & Neck Cancers